PDCD1 and nasopharyngeal carcinoma: In RM-NPC patients who had progressed on first-line treatment, anti-programmed cell death 1 (anti-PD-1) monotherapy showed promising antitumor activity, with objective response rates (ORRs) of 13–43% and median duration of response longer than 8 months [6].